Obregón FAM, Muñoz NK, Echevarría PE, Rodríguez OY, Rodríguez SJ, Valdés LY, Baly GA, Toledo RME

Language: Spanish
References: 9
Page:
PDF size: 153.59 Kb.

ABSTRACT

Introduction: brucellosis is a zoonosis detrimental to human and animal health. Cuba increases food-producing uncontrolled stockbreeding, a fact that, together with other farming activities, influences the increase in morbidity for this disease. The Cuban national network of public health laboratories lacks laboratory methods for diagnosis human brucellosis.
Objectives: to qualitatively evaluate the commercial serological system Febrile Antigen Brucella for the detection of anti-Brucella antibodies, with the use of serums from cases and controls; to confirm Brucella infection, by means of the application of the commercial serological system for anti-Brucella antibodies detection and the commercial systems of reference ELISA-IgM and ELISA-IgG in serums from patients suspected of brucellosis; and to partially describe the costs of the commercial serological system Febrile Antigen Brucella.
Methods: observational research carried out in services and systems, by a nested case-control study, with 40 serums from cases, 80 controls and 466 samples from suspect patients, in order to evaluate the commercial system Febrile Antigen Brucella (Diagnostica Senese SpA), which besides was object to a partial economic evaluation of costs. As reference tests, ELISA-IgM and ELISA-IgG (VIRCELL, España) were used.
Results: the Febrile Antigen Brucella system showed sensitivity values of 100.00%, specificity of 97.50% and agreement coefficient of 98.33%. Out of the 72 clinical cases, 25 presented titles greater than or equal to 160 by Febrile Antigen Brucella and were positive also by ELISA-IgM and ELISA-IgG. The use of the systems ELISA-IgM and ELISA-IgG in Febrile Antigen Brucella-reactive and suspect serums increased serological positivity. Mean average cost (21.46 CUP) for one determination by Febrile Antigen Brucella proved economical.
Conclusion: The laboratory diagnosis of human brucellosis in Cuba becomes stronger upon proving that Febrile Antigen Brucella has an economical cost and that it is useful for anti-Brucella antibodies detection.

REFERENCES

1. Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. Lancet Infect Dis. 2007;7:775–86.

2. Cruz de la Paz R, Gandul L, Blanco MO, Machado O, Rodríguez C, Seoane G, et al. Programa Nacional de Prevención y Control de Brucelosis humana. Segunda versión. La Habana: MINSAP; 1998.

3. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. La Habana: MINSAP; 2012.

4. VIRCELL SL. España. Brucella ELISA IgM. Brucella ELISA IgG. Taller Nacional de Laboratorio para el Diagnóstico de Brucelosis humana. La Habana: MINSAP. 11 Mar 2012 [citado 12 Mar 2014]. Disponible en:www.vircell.com

5. DIESSE, Diagnostica Senese SpA. Italia. Febrile Antigen Brucella [citado en el Taller Nacional de Laboratorio para el Diagnóstico de Brucelosis humana. La Habana: MINSAP. 11 Mar 2012 [citado 12 Mar 2014]. Disponible en: www.diesse.com

6. Baly A. Costo y costo-efectividad de estrategias comunitarias para el control de Aedes Aegypti y la prevención del dengue. [Tesis presentada en opción al grado científico de Doctor Ciencias de la Salud]. La Habana: IPK; 2010.

7. Dashti AS, Karimi A, Javadi V, Shiva F, Fallah F, Alaei MR, et al. ELISA cut-off point for the diagnosis of human brucellosis; a comparison with serum agglutination test. Iran J Med Sci. 2012;37(1):9-14.

8. Pabuccuoglu O, Ecemis T, El S, Coskun A, Akcali S, Sanlidag T, et al. Evaluation of serological tests for diagnosis of brucellosis. Jpn J Infect Dis. 2011;64(4):272-6.

9. Gómez MC, Nieto JA, Rosa C, Geijo P, Escribano MA, Muñoz A, et al. Evaluation of seven tests for diagnosis of human brucellosis in an area where the disease is endemic. Clin Vaccine Immunol. 2008;15:1031–3.